P. Andrew Futreal

TL;DR: Genome-wide methylation comparison among MPAL, AML, B-ALL, and T-ALL sub-classifies MPAL into AML-type and ALL-type MPAL which is associated with better clinical response when lineage-matched therapy is given, and provides proof of concept for a molecularly guided precision therapy approach in MPAL.

TL;DR: In this article , a group of patients with melanoma who were treated with neoadjuvant BRAF/MEK-targeted therapy (NCT02231775 , n = 51) and observed significantly higher rates of major pathological response (MPR; ≤ 10% viable tumour at resection) and improved recurrence-free survival (RFS) in female versus male patients.

TL;DR: The findings indicate that BRCA1/2 germline mutation may contribute to widespread structural change and that other undefined mechanism(s), which are potentially shared with triple‐negative breast cancer, promote tandem chromosomal duplications that sculpt the ovarian cancer genome.

TL;DR: An integrated proteogenomic analyses of ACC tumors to identify dysregulated pathways and propose a classification with therapeutic implications suggests a model in which ACC-I is driven by MYC signaling through either NOTCH mutations or direct amplification, which in turn suppress P63 signaling observed in ACC-II, producing unique therapeutic vulnerabilities for each subtype.